We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stericycle (SRCL) Hits New 52-Week High: What's Driving It?
Read MoreHide Full Article
Shares of Stericycle, Inc. (SRCL - Free Report) scaled a new 52-week high of $65.49 in the trading session on Dec 5, before closing a tad lower at $64.93.
The company’s shares have charted a solid trajectory in recent times, appreciating 77.1% year to date, ahead of the 22.6% growth of the industry it belongs to.
Notably, Stericycle has witnessed a 12.8% rise in share price since it posted third-quarter 2019 results.
Let’s find out what’s supporting the uptick.
Strategic Acquisitions Bode Well
Stericycle’s acquisition pool remains robust in multiple geographies and lines of business. The company had completed 21, 30 and 31 acquisitions, respectively, in 2018, 2017 and 2016.
Global acquisition strategy increases Stericycle’s customer base by providing a long-term growth platform for selling multiple services. In 2018, 2017 and 2016, acquisitions contributed $29.7 million, $32.2 million and $570.1 million to revenues, respectively. In the first nine months of 2019, acquisitions contributed $9.3 million to revenues.
The company is continuously on the lookout for acquisitions that will grow its market share and expand geographic base.
Multiyear Business Transformation Scheme: A Key Catalyst
Stericycle is progressing well with its comprehensive multiyear Business Transformation, aimed at improving long-term operational and financial performance.
As part of the portfolio rationalization strategy within Business Transformation, Stericycle completed five divestitures — the North American telephone answering services business, a retail pharmaceutical returns business, all of its Mexican operations, its remaining hazardous waste business in the United Kingdom and the U.S. non-core clean room services business — since its initiation in 2017.
The company is looking for alternatives for the CRS business and other non-core assets and geographies. It has divested the U.K.-based texting business, which had been part of CRS. The company is progressing well with the ERP implementation.
Evidently, Stericycle earned $38.1 million of gross proceeds (from the divestitures completed during October 2019) and plans to use it to reduce net debt in the fourth quarter of 2019.
Updated 2019 EPS Guidance
Stericycle raised the low end of its adjusted earnings per share guidance for 2019. Adjusted EPS for 2019 is now anticipated to be $2.55-$2.70 million compared with the previously guided range of $2.50-$2.85 million.
Zacks Rank & Stocks to Consider
Currently, Stericycle carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Business Services sector are Global Payments (GPN - Free Report) , Mastercard (MA - Free Report) and Cardtronics . While Global Payments and Cardtronics sport a Zacks Rank #1 (Strong Buy), Mastercard carries a Zacks Rank #2 (Buy).
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Stericycle (SRCL) Hits New 52-Week High: What's Driving It?
Shares of Stericycle, Inc. (SRCL - Free Report) scaled a new 52-week high of $65.49 in the trading session on Dec 5, before closing a tad lower at $64.93.
The company’s shares have charted a solid trajectory in recent times, appreciating 77.1% year to date, ahead of the 22.6% growth of the industry it belongs to.
Notably, Stericycle has witnessed a 12.8% rise in share price since it posted third-quarter 2019 results.
Let’s find out what’s supporting the uptick.
Strategic Acquisitions Bode Well
Stericycle’s acquisition pool remains robust in multiple geographies and lines of business. The company had completed 21, 30 and 31 acquisitions, respectively, in 2018, 2017 and 2016.
Global acquisition strategy increases Stericycle’s customer base by providing a long-term growth platform for selling multiple services. In 2018, 2017 and 2016, acquisitions contributed $29.7 million, $32.2 million and $570.1 million to revenues, respectively. In the first nine months of 2019, acquisitions contributed $9.3 million to revenues.
The company is continuously on the lookout for acquisitions that will grow its market share and expand geographic base.
Multiyear Business Transformation Scheme: A Key Catalyst
Stericycle is progressing well with its comprehensive multiyear Business Transformation, aimed at improving long-term operational and financial performance.
As part of the portfolio rationalization strategy within Business Transformation, Stericycle completed five divestitures — the North American telephone answering services business, a retail pharmaceutical returns business, all of its Mexican operations, its remaining hazardous waste business in the United Kingdom and the U.S. non-core clean room services business — since its initiation in 2017.
The company is looking for alternatives for the CRS business and other non-core assets and geographies. It has divested the U.K.-based texting business, which had been part of CRS. The company is progressing well with the ERP implementation.
Evidently, Stericycle earned $38.1 million of gross proceeds (from the divestitures completed during October 2019) and plans to use it to reduce net debt in the fourth quarter of 2019.
Updated 2019 EPS Guidance
Stericycle raised the low end of its adjusted earnings per share guidance for 2019. Adjusted EPS for 2019 is now anticipated to be $2.55-$2.70 million compared with the previously guided range of $2.50-$2.85 million.
Zacks Rank & Stocks to Consider
Currently, Stericycle carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Business Services sector are Global Payments (GPN - Free Report) , Mastercard (MA - Free Report) and Cardtronics . While Global Payments and Cardtronics sport a Zacks Rank #1 (Strong Buy), Mastercard carries a Zacks Rank #2 (Buy).
Long-term expected EPS (three to five years) growth rate for Global Payments, Mastercard and Cardtronics is 17.3%, 16% and 4%, respectively. You can see the complete list of today’s Zacks #1 Rank stocks here.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>